Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Bristol-Myers Squibb Co (NYSE: BMY) closed the day trading at $46.47 up 1.93% from the previous closing price of $45.59. In other words, the price has increased by $1.93 from its previous closing price. On the day, 11.73 million shares were traded. BMY stock price reached its highest trading level at $46.625 during the session, while it also had its lowest trading level at $45.425.
Ratios:
For a better understanding of BMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.18. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 2.75 whereas as Long-Term Debt/Eq ratio is at 2.50.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $55 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when Elkins David V sold 56,000 shares for $47.33 per share. The transaction valued at 2,650,480 led to the insider holds 167,379 shares of the business.
Elkins David V bought 56,000 shares of BMY for $2,648,800 on Sep 02 ’25. On Aug 02 ’25, another insider, Short Bartie Wendy, who serves as the EVP, Corporate Affairs of the company, sold 378 shares for $44.23 each. As a result, the insider received 16,719 and left with 5,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 94601445376 and an Enterprise Value of 129188446208. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.69, and their Forward P/E ratio for the next fiscal year is 7.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.97 while its Price-to-Book (P/B) ratio in mrq is 5.10. Its current Enterprise Value per Revenue stands at 2.69 whereas that against EBITDA is 6.723.
Stock Price History:
The Beta on a monthly basis for BMY is 0.31, which has changed by -0.16669714 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.52. The 50-Day Moving Average of the stock is 2.63%, while the 200-Day Moving Average is calculated to be -7.17%.
Shares Statistics:
Over the past 3-months, BMY traded about 14.53M shares per day on average, while over the past 10 days, BMY traded about 19539590 shares per day. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.06% of the company’s shares, while institutions hold 83.20% stake in the company. Shares short for BMY as of 1760486400 were 30358285 with a Short Ratio of 2.09, compared to 1757894400 on 29470983. Therefore, it implies a Short% of Shares Outstanding of 30358285 and a Short% of Float of 1.49.
Dividends & Splits
BMY’s forward annual dividend rate is 2.48, up from 2.48 a year ago. Against a Trailing Annual Dividend Yield of 0.054397896. The stock’s 5-year Average Dividend Yield is 3.79.
Earnings Estimates
Bristol-Myers Squibb Co (BMY) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $1.5, with high estimates of $1.86 and low estimates of $1.23.
Analysts are recommending an EPS of between $6.68 and $6.45 for the fiscal current year, implying an average EPS of $6.55. EPS for the following year is $6.01, with 25.0 analysts recommending between $7.27 and $5.12.
Revenue Estimates
13 analysts predict $12.27B in revenue for. The current quarter. It ranges from a high estimate of $12.53B to a low estimate of $12.02B. As of. The current estimate, Bristol-Myers Squibb Co’s year-ago sales were $12.34BFor the next quarter, 13 analysts are estimating revenue of $10.51B. There is a high estimate of $11.38B for the next quarter, whereas the lowest estimate is $10.08B.
A total of 20 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $48.23B, while the lowest revenue estimate was $47.46B, resulting in an average revenue estimate of $47.97B. In the same quarter a year ago, actual revenue was $48.3BBased on 25 analysts’ estimates, the company’s revenue will be $44B in the next fiscal year. The high estimate is $47.74B and the low estimate is $41.97B.
